Basak 2001.

Methods	Study type: individual RCT Randomisation method: not reported Blinding: not reported Intention‐to‐treat analysis used: not reported
Participants	Inclusion criteria of the trial Not reported, but all had seborrhoeic dermatitis of the scalp clinically characterised by erythema, scaling, and itching Exclusion criteria of the trial Not reported Number of randomised participants: 60 in total (betamethasone N = 30, calcipotriol N = 30) Number of dropouts: 7, all from 1 treatment arm (23%) Sex: not reported Age: not reported Country: Turkey
Interventions	Treatment Calcipotriol solution 50 μg/ml, applied on the scalp twice daily for 28 days Comparator/s Betamethasone 17‐valerate 1 mg/ml, applied on the scalp twice daily for 28 days If there was only slight improvement at the end of 4 weeks, treatment was continued for another 4‐week period After cessation of treatment, participants entered a follow‐up period for 4 weeks Before the start of treatment, there was a 1‐week wash‐out period, during which only a mild non‐medicated shampoo was used
Outcomes	Severity of erythema, scaling, and itching of the scalp rated on a 4‐point scale (0 to 3) Total clearance Total score (the sum of the individual scores) Adverse events Routine biochemical analysis including serum total calcium levels
Notes	Results were reported mainly at 4 weeks. The dropout rate was unbalanced and considerable
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	This was not reported in detail Quote: "randomly assigned"
Allocation concealment (selection bias)	Unclear risk	This was not reported
Similarity of the study groups (selection bias)	Unclear risk	This was not reported in sufficient detail
Blinding of participants (performance bias)	High risk	There was no mention of blinding in the report
Blinding of care providers (performance bias)	High risk	There was no mention of blinding in the report
Blinding of outcome assessment (detection bias) All outcomes	High risk	There was no mention of blinding in the report
Incomplete outcome data (attrition bias) All outcomes	High risk	More than 20% of participants withdrew from the calcipotriol arm
Selective reporting (reporting bias)	Unclear risk	Not all results related to predefined outcomes were reported in sufficient detail
Other bias	Unclear risk	No other bias was identified